VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis
Information source: Bayer
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Bronchitis; Disease Exacerbation
Intervention: Moxifloxacin (Avelox, BAY12-8039) (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
This study is a local, prospective, open-label, company-sponsored, non interventional,
multi-center study. Patients documented must suffer from an acute exacerbation of chronic
bronchitis and take at least one dose of Moxifloxacin injection. The primary objective is to
obtain clinical effectiveness and safety data of Moxifloxacin injection in the treatment of
acute exacerbations of chronic bronchitis in patients in whom Moxifloxacin was routinely
prescribed. The secondary objective is to find out the possible correlation between the risk
factors (sex, smoking, number of previous exacerbations, etc) and AECB, the different
treatment effectiveness according to Anthonisen classification. This study will also collect
the data of pathogens by sputum culture and the defervescence time of Moxifloxacin injection
in treating Acute Exacerbations of Chronic Bronchitis (AECB).
Clinical Details
Official title: VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis
Study design: Cohort, Prospective
Primary outcome: Effectiveness related variables will be sputum culture, defervescence time, time to improvement, time to cure, as well as the general assessment of effectiveness by physicians and general assessment of therapeutic effect by physicians and patients
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients at least 18 years of age with a diagnosis of AECB treated with Moxifloxacin
injection with/without sequential tablet treatment
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Many Locations, China; Recruiting
Additional Information
Click here and search for drug information provided by the FDA Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product Click here to find results for studies related to marketed products
Starting date: May 2009
Ending date: October 2010
Last updated: October 1, 2009
|
